{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-094756","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2024-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.491697+00:00","generated_at":"2026-06-03T23:33:10.859476+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Sensei Bio enters consulting agreement with former CFO Erin Colgan for transition through April 30, 2024","bullets":["Erin Colgan, former CFO, will provide transition services through April 30, 2024 under a consulting agreement.","Consulting fee of $1,640 per business day.","Exercise period for her existing vested stock options extended to October 7, 2024 or later per plan/award.","Agreement expires automatically on April 30, 2024 unless terminated earlier."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-094756","json":"https://secwatch.observer/filing/0001193125-24-094756.json","markdown":"https://secwatch.observer/filing/0001193125-24-094756.md","text":"https://secwatch.observer/filing/0001193125-24-094756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524094756/0001193125-24-094756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524094756/d796542d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T23:33:10.859476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"daf7c3d0a5","claim":"Erin Colgan departed as Chief Financial Officer at Sensei Biotherapeutics, Inc..","evidence_excerpt":"On April 11, 2024, Sensei Biotherapeutics, Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with Erin Colgan, the Company’s former Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524094756/0001193125-24-094756-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}